Skip to main content

Table 3 Univariable and multivariable analysis with respect to disease-free survival in breast cancer subtypes

From: Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden

  

Univariable analysis

Multivariable analysis

Parameter

 

Hazard ratio

95% c.i.

p value

Hazard ratio

95% c.i.

p value

All breast cancers (n = 177)

 Age

≤56 vs >56

0.809

0.395–1.657

0.561

   

 Menopause

Pre- vs Post-

0.840

0.408–1.731

0.637

   

 Tumor size (cm)

≤2 vs >2

1.062

0.370–3.045

0.911

   

 Lymph node status

Negative vs Positive

4.157

0.990–17.456

0.052

   

 Nuclear grade

1–2 vs 3

1.025

0.440–2.389

0.954

   

 Ki67 (%)

≤14 vs >14

0.649

0.316–1.331

0.238

   

 Intrinsic subtype

TNBC vs non-TNBC

1.213

0.577–2.550

0.611

   

 Intrinsic subtype

HER2BC vs non- HER2BC

0.695

0.266–1.818

0.459

   

 Intrinsic subtype

HRBC vs non-HRBC

1.054

0.514–2.160

0.886

   

 Pathological response

pCR vs non-pCR

0.611

0.279–1.336

0.217

1.008

0.402–2.524

0.987

 TILs

High vs Low

0.420

0.199–0.885

0.022

4.785

1.169–19.582

0.029

 RCB-TILs

Positive vs Negative

0.181

0.082–0.401

<0.001

0.048

0.012–0.188

<0.001

TNBC (n = 61)

 Age

≤56 vs >56

0.690

0.211–2.262

0.541

   

 Menopause

Pre- vs Post-

0.652

0.199–2.136

0.480

   

 Tumor size (cm)

≤2 vs >2

0.550

0.119–2.546

0.444

   

 Lymph node status

Negative vs Positive

0.942

0.203–4.359

0.939

   

 Nuclear grade

1–2 vs 3

1.553

0.455–5.307

0.482

   

 Ki67 (%)

≤14 vs >14

0.739

0.216–2.526

0.630

   

 Pathological response

pCR vs non-pCR

0.234

0.050–1.084

0.063

0.270

0.030–2.466

0.246

 TILs

High vs Low

0.177

0.054–0.583

0.004

0.243

0.071–0.816

0.023

 RCB-TILs

Positive vs Negative

0.099

0.029–0.343

<0.001

0.041

0.003–0.573

0.018

HER2BC (n = 36)

 Age

≤56 vs >56

1.245

0.207–7.493

0.811

   

 Menopause

Pre- vs Post-

2.507

0.280–22.443

0.411

   

 Tumor size (cm)

≤2 vs >2

0.693

0.081–6.302

0.744

   

 Lymph node status

Negative vs Positive

3.732

0.072–5.051

0.414

   

 Nuclear grade

1–2 vs 3

0.043

0.011–5.216

0.513

   

 Ki67 (%)

≤14 vs >14

0.441

0.068–2.623

0.364

   

 Pathological response

pCR vs non-pCR

0.482

0.078–2.847

0.415

0.702

0.108–4.551

0.710

 TILs

High vs Low

0.123

0.020–0.774

0.026

0.134

0.020–0.879

0.036

 RCB-TILs

Positive vs Negative

0.123

0.020–0.774

0.026

0.134

0.020–0.879

0.036

HRBC (n = 80)

 Age

≤56 vs >56

0.856

0.297–2.467

0.773

   

 Menopause

Pre- vs Post-

0.769

0.270–2.193

0.623

   

 Tumor size (cm)

≤2 vs >2

2.462

0.322–18.836

0.386

   

 Lymph node status

Negative vs Positive

3.682

0.151–10.382

0.205

   

 Nuclear grade

1–2 vs 3

1.063

0.303–3.811

0.930

   

 Ki67 (%)

≤14 vs >14

0.602

0.212–1.738

0.344

   

 Pathological response

pCR vs non-pCR

1.328

0.438–3.973

0.614

2.123

0.667–6.750

0.202

 TILs

High vs Low

0.992

0.311–3.165

0.990

1.044

0.323–3.372

0.949

 RCB-TILs

Positive vs Negative

0.258

0.071–0.932

0.039

0.081

0.016–0.409

0.002

  1. c.i confidence interval, TILs tumor-infiltrating lymphocytes, RCB residual cancer burden, TNBC triple-negative breast cancer, HER2BC human epidermal growth factor receptor 2-enriched breast cancer, HRBC hormone receptor-positive breast cancer, pCR pathological complete response